CoLucid Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference

CAMBRIDGE, Mass., Sept. 26, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, with or without aura, announced today it will provide a corporate overview at the Ladenburg Thalmann 2016 Healthcare Conference, being held in New York City on September 27, 2016.

About CoLucid Pharmaceuticals, Inc.CoLucid was founded in 2005 and is developing lasmiditan oral tablets for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.

CONTACT
Thomas Mathers
Chief Executive Officer
CoLucid Pharmaceuticals, Inc.
(857) 285-6494

Hans Vitzthum
Managing Director
LifeSci Advisors, LLC.
(212) 915-2568

You May Also Be Interested In

• Litecoin Price Prediction: LTC Holds Above $70 as $100 Remains a Bull Scenario and Remittix Opens BINANCE500
• ProPeptide Expands Transparency Initiative With Published Batch-Level Testing
• Luxury Spray Tan Boca Raton Defined by Private One-on-One Session Structure